Stockscreener 앱 받기
26.37
8.41%
-2.42
전일 마감가:
$28.79
열려 있는:
$28.47
하루 거래량:
1.21M
Relative Volume:
5.26
시가총액:
$326.54M
수익:
$9.71M
순이익/손실:
$-29.96M
주가수익비율:
-7.5776
EPS:
-3.48
순현금흐름:
$-14.79M
1주 성능:
-11.66%
1개월 성능:
+2.09%
6개월 성능:
-0.90%
1년 성능:
-3.37%
1일 변동 폭
$26.32
$29.46
1주일 범위
$24.40
$29.57
52주 변동 폭
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
명칭
Xoma Royalty Corp
전화
510-204-7239
주소
2200 POWELL STREET, EMERYVILLE, CA
XOMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
26.37 | 356.51M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | The Benchmark Company | Buy |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2021-09-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-06-29 | 개시 | Aegis Capital | Buy |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-17 | 재개 | H.C. Wainwright | Buy |
| 2017-09-05 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2017-06-12 | 개시 | H.C. Wainwright | Buy |
| 2016-11-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-11 | 재확인 | Wedbush | Outperform |
| 2015-07-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-07-22 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | 재개 | ROTH Capital | Buy |
| 2014-04-29 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-03-11 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2014-03-05 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-10-31 | 재확인 | MLV & Co | Buy |
| 2013-05-09 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-14 | 개시 | Cowen & Co | Outperform |
| 2011-03-31 | 재확인 | MLV Capital | Buy |
| 2011-03-23 | 재확인 | RBC Capital Mkts | Outperform |
| 2011-01-06 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-01-04 | 재확인 | Wedbush | Outperform |
모두보기
Xoma Royalty Corp 주식(XOMA)의 최신 뉴스
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA royalty announces CFO transition - MSN
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
XOMA Royalty Announces CFO Transition - Yahoo Finance
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
Implied Volatility Surging for XOMA Royalty Stock Options - Yahoo Finance
XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts - Defense World
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab - Yahoo Finance
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Two XOMA preferred share classes pay cash to holders in January - Stock Titan
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - Nasdaq
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
Xoma announces closing of transactions to acquire Lava Therapeutics - MSN
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com Canada
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday?Rezolute (NASDAQ:RZLT), XOMA Royalty (NASDAQ:XOMA) - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Xoma Royalty Corp (XOMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xoma Royalty Corp 주식 (XOMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sitko Bradley | Chief Investment Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
6,712 |
0 |
19,822 |
| Hughes Owen | Chief Executive Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
35,567 |
0 |
98,268 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 19 '25 |
Option Exercise |
0.00 |
11,846 |
0 |
34,409 |
| BURNS THOMAS M. | SVP, Finance & CFO |
Sep 22 '25 |
Sale |
35.99 |
4,330 |
155,820 |
30,079 |
| Montano Maricel Perea | Chief Legal Officer |
Sep 19 '25 |
Option Exercise |
0.00 |
3,033 |
0 |
12,134 |
| Montano Maricel Perea | Chief Legal Officer |
Sep 10 '25 |
Option Exercise |
0.00 |
9,101 |
0 |
9,101 |
| Sitko Bradley | Chief Investment Officer |
Jun 30 '25 |
Buy |
25.39 |
2,000 |
50,780 |
7,045 |
| Hughes Owen | Chief Executive Officer |
May 19 '25 |
Option Exercise |
0.00 |
53,359 |
0 |
88,338 |
| Hughes Owen | Chief Executive Officer |
May 20 '25 |
Sale |
25.38 |
25,637 |
650,667 |
62,701 |
| BURNS THOMAS M. | SVP, Finance & CFO |
May 19 '25 |
Option Exercise |
0.00 |
17,773 |
0 |
33,045 |
4.73%
0.92%
자본화:
|
볼륨(24시간):